leisure time -WSS

leisure time

author：fashion 2025-09-28 21:56:52 - browse：815

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout LOUD podcast: ALS dilemma, first MASH drug, and more

WSS

HHS secretary Becerra pressed on Change HealthCare cyberattack

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

FDA gives detailed accounting of AI

Senate committee scrutinizes Medicare Advantage brokers

CEOs share strategies for surviving biotech slump

How to save health care price transparency rules

leisure time

leisure time

knowledge

23andMe had bad news about my health. I wish a person had delivered it

STAT Summit: Michael J. Fox on progress in Parkinson's research

Activists slam private health insurers over coverage restrictions

UCLA team creates talking throat patch for voice disorders

Sports medicine is finally prioritizing gender equality

Lawmakers consider Medicare pay reforms for doctors

Guidelines to prevent youth baseball injuries need more muscle

STAT Readout Newsletter: Today's biggest biotech updates

Heart attack and stroke risk calculators need revising

Eli Lilly expects to double planned employment in Boston center

explore

FDA warns J&J's Abiomed: We will regulate your software

FDA gives detailed accounting of AI

UnitedHealth’s board chair also owns a personal investment firm

As AI in medicine takes off, can 'human in the loop' prevent harm?

John Green on his newest strategy for fighting tuberculosis

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Wikipedia

knowledge

hotspot

hotspot